On Tuesday, Zydus Life shares closed at Rs 903.1, up 1.1% on the BSE, while the benchmark Sensex surged 1.53%. The stock has ...

The rise in the Zydus Lifesciences shares came after the company received final approval from the United States Food and Drug ...

Brokerage firms remain divided on Zydus Lifesciences as the company announced to acquire France-based Amplitude Surgical for ...

Nuvama is of the view that the Zydus Life's latest deal would be dilutive to the company's Earnings Per Share (EPS) by 1% to ...

Brokerages deemed Zydus Life's acquisition of Amplitude Surgical as expensive, with subpar synergies that has triggered ...

Zydus Lifesciences is working to advance its position in the global pharmaceutical sector by increasing its focus on medical ...

India still relies largely on imported devices and implants, when it comes to MedTech. This offers us a great opportunity to ...

Zydus Lifesciences shares rose 8.34 per cent on March 19, touching an intraday high of Rs 910.30  at 1:00 PM when the company ...

As per the IQVIA MAT January 2025 data, apalutamide tablets registered annual sales of $1099.80 million in the United States markets.

The purchase price is €6.25 per share of equity, putting the transaction value at €256.8 million for the 85.6% stake.

Zydus Lifesciences on Tuesday said it has entered into negotiations to acquire a majority stake in France-based Amplitude ...

Zydus Lifesciences Ltd has received USFDA approval to manufacture a generic version of Apalutamide tablets for prostate cancer treatment. The 60 mg tablets will be produced in Ahmedabad, addressing a ...